1 week Ago By Defense World Staff
Kura Oncology (NASDAQ:KURA – Get Free Report)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a report released on Tuesday,RTT News reports. They presently have a $36.00 target price on the stock.
A number of other equities analysts have also commented on the stock. Scotiabank cut their price objective on shares of Kura Oncology from $18.00 to $10.
00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th.
JMP Securities reissued a “market outperform” rating and issued a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. BTIG Research downgraded Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th.
Finally, Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $25.
50.Check Out Our Latest Analysis on Kura OncologyKura Oncology Price PerformanceKURA stock opened at $5.97 on Tuesday.
The firm has a market cap of $482.11 million, a P/E ratio of -2.53 and a beta of 0.
83. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.
47 and a current ratio of 11.47. Kura Oncology has a 1 year low of $5.
41 and a 1 year high of $23.48. The stock has a 50-day simple moving average of $7.
47 and a 200-day simple moving average of $11.06. Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th.
The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.
43. The firm had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.
96 million. On average, equities analysts predict that Kura Oncology will post -2.44 earnings per share for the current fiscal year.
Insider Buying and Selling at Kura OncologyIn other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.
63. Following the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91.
This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.
81. Following the completion of the transaction, the insider now owns 88,253 shares of the company’s stock, valued at approximately $694,551.11.
The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here.
Insiders sold a total of 11,729 shares of company stock worth $92,307 over the last 90 days. Insiders own 5.50% of the company’s stock.
Institutional Trading of Kura OncologySeveral hedge funds have recently made changes to their positions in the stock. Virtus ETF Advisers LLC increased its position in Kura Oncology by 71.6% in the fourth quarter.
Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after buying an additional 3,061 shares during the period. Harbor Advisors LLC acquired a new position in Kura Oncology during the 4th quarter valued at about $87,000. E Fund Management Co.
Ltd. bought a new position in Kura Oncology in the 4th quarter worth about $90,000. Corton Capital Inc.
bought a new position in Kura Oncology in the 4th quarter worth about $99,000. Finally, Optimize Financial Inc acquired a new stake in shares of Kura Oncology in the fourth quarter valued at approximately $100,000. About Kura Oncology (Get Free Report)Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.Featured StoriesFive stocks we like better than Kura OncologyHow to Calculate Return on Investment (ROI)Quantum Computing: The $6.
5 Billion Opportunity You Can’t Ignore3 Best Fintech Stocks for a Portfolio BoostAre Tariffs Threatening Disney’s Comeback Story?Mastering Discipline: Overcoming Emotional Challenges In TradingIs Alphabet a Generational Buying Opportunity at These Levels?.
